迷思终结-3:根据分子分析,根据avelumab免疫疗法的疗效在一线子宫内膜癌治疗中
S Pignata1, D Califano2, D Lorusso3
1Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples.
概括
像TP53,PTEN和ARID1A突变这样的生物标志物可以预测晚期子宫内膜癌 (EC) 中的免疫治疗反应. 这项研究确定了在使用阿维卢马布与化疗时与更好或更差的结果相关的特定突变.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 翻译研究是翻译研究.
背景情况:
- 免疫疗法和化疗改善了晚期子宫内膜癌 (EC) 的无进展生存期 (PFS),特别是在微卫星不稳定性高 (MSI-H) 的病例中.
- 识别微卫星稳定 (MSS) 瘤的生物标志物可以优化患者选择治疗效益.
研究的目的:
- 调查基因组异常在预测对第一线化疗加上AVELUMAB在高级EC的反应中的意义.
- 为了在MITO END-3试验中确定患者选择的新生物标志物.
主要方法:
- 通过对MITO END-3试验的翻译分析,评估了在接受加博普拉丁/帕克利塔克塞尔与或没有阿维卢马布的患者中的基因组异常.
- 下一代测序对109名患者样本进行,对102名患者进行MSI测试.
主要成果:
- TP53突变与对阿维卢马布的反应不佳有关,而PTEN和ARID1A突变显示出与治疗益处的统计学上显著的积极相互作用.
- 在MSI-H患者和一些MSS/TP53突变病例中,瘤突变负担很高.
- 阿维卢马布对PFS的影响因TCGA基因组类别而异,有利于MSI-H,在MSS/TP53突变患者中恶化.
结论:
- TP53突变表明晚期EC患者对阿维卢马布的反应不佳.
- PTEN和ARID1A的突变与对阿维卢马布的积极反应有关,这表明它们作为预测生物标志物的潜力.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.5K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K